VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson's disease

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Valosin-containing protein (VCP/p97) is crucial for protein homeostasis and quality control.
• Dysfunctional VCP is implicated in the pathogenesis of neurodegenerative disorders, including Parkinson's disease (PD).

Purpose of the Study:

• To investigate the role of VCP expression changes in the early stages of Parkinson's disease.
• To determine if VCP mRNA levels can serve as a biomarker for preclinical and early clinical PD.

Main Methods:

• Analysis of Vcp gene expression in various tissues of mice with toxin-induced PD.
• Quantification of VCP expression in blood samples from PD patients and healthy controls.
• Comparison of VCP expression across different stages of PD, including preclinical and early clinical phases.

Main Results:

• Significant alterations in Vcp gene expression were observed in most mouse tissues studied.
• A notable decrease in VCP expression specific to PD was detected in untreated patients at both preclinical and early clinical stages.
• Reduced VCP mRNA levels were consistently found in PD patients and in mouse models of PD.

Conclusions:

• Decreased VCP expression is a significant finding associated with early-stage Parkinson's disease.
• Relative VCP mRNA levels show potential as a diagnostic biomarker for identifying PD pathology at its earliest stages.